Prostate-specific antigen: its clinical use and application in screening for prostate cancer

Bangma, C.H.; Blijenberg, B. G.; Schröder, Fritz H.

doi:10.3109/00365519509090562

Cited by 10 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S-PSA relates to a number of aspects of the disease and can be helpful in the early diagnosis of prostate cancer and in staging of locally confined disease, and can give an indication of the presence of lymph node metastases [2]. During watchful waiting regimen or during therapy, S-PSA is the most reliable marker for surveillance.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy

et al. 1999

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

“…During watchful waiting regimen or during therapy, S-PSA is the most reliable marker for surveillance. However, there are drawbacks to S-PSA, and it is considered to be of less value for prognostic purposes [2].…”

Section: Introductionmentioning

confidence: 99%

Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy

et al. 1999

View full text Add to dashboard Cite

“…In the last decade, as the incidence of prostate cancer has increased with the aging of the western male population, so has its detection improved with the introduction of prostate-specific antigen serum testing and a growing awareness of the disease (Bangma et al, 1995). Concern has been raised about the potential risk of overtreatment of early-detected prostate cancers (De Koning and Schrö der 1998;Zappa et al, 1998).…”

mentioning

confidence: 99%

Silencing of CD44 Expression in Prostate Cancer by Hypermethylation of the CD44 Promoter Region

Verkaik

Steenbrugge

Weerden

et al. 2000

Laboratory Investigation

View full text Add to dashboard Cite

SUMMARY:Loss of the CD44 transmembrane glycoprotein in primary prostate cancer has been shown to be associated with unfavorable clinical behavior. Moreover, the majority of prostate cancer metastases lack expression of this molecule. The mechanism of CD44 silencing in prostate cancer was investigated using both patient material and in vivo-propagated human prostate cancer xenografts. In 9 of 11 lymph node metastases of prostate cancer, we demonstrated by methylation-sensitive restriction enzyme digestion that the promoter region of the CD44 gene is methylated, indicating that this represents a major mechanism of CD44 silencing. Similarly, in 6 out of 12 in vivo-growing human prostate carcinoma xenograft models, hypermethylation of the CD44 gene was found. The extent of CpG island methylation was investigated by nucleotide sequencing after bisulphite modification of the CD44 promoter region. In the xenografts displaying hypermethylation, the examined 14 CpG sites in the CD44 transcription regulatory domain, including a Sp1 binding site, were consistently methylated. This correlated with reduced CD44 expression or lack of CD44 expression at mRNA and protein levels. In the xenografts lacking hypermethylation of the CD44 gene, high levels of CD44 mRNA and protein were expressed in some models, whereas in others CD44 mRNA expression was only detectable by RT-PCR and the CD44 protein could hardly be detected or was not detected at all. The results indicate that, in most prostate cancers, loss of CD44 expression is associated with extensive hypermethylation of the CpG island of the CD44 promoter region, but other, posttranscriptional mechanisms may also lead to CD44 loss. (Lab Invest 2000, 80:1291-1298.

show abstract

“…increasing serum PSA values are a reliable indicator of tumour progression. However, there are drawbacks to using serum PSA and it is considered to be of less value for diagnostic and prognostic purposes [2]. In our studies with a hormone-sensitive cell-line (LNCaP) and a hormone-resistant cell-line (LNCaP-r), we found indications that the measurement of intracellular PSA could be of value as a predictive test [3].…”

Section: Introductionmentioning

confidence: 83%

“…Serum PSA relates to several aspects of the disease and can be helpful in the early diagnosis of prostate cancer and in the staging of locally confined disease. and can give an indication of the presence of lymph node metastases [2]. Moreover, during a watchful waiting regimen or during therapy, serum PSA is the most reliable marker for surveillance.…”

Section: Introductionmentioning

confidence: 99%

Prostate‐specific antigen in tissue from fine‐needle aspiration biopsies

Pousette

Carlström

Tribukait

et al. 1997

British Journal of Urology

View full text Add to dashboard Cite

Prostate-specific antigen: its clinical use and application in screening for prostate cancer

Cited by 10 publications

References 37 publications

Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy

Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy

Silencing of CD44 Expression in Prostate Cancer by Hypermethylation of the CD44 Promoter Region

Prostate‐specific antigen in tissue from fine‐needle aspiration biopsies

Contact Info

Product

Resources

About